Chip In Early detection is often critical to surviving…

Chip In

Early detection is often critical to surviving cancer, making methods of diagnosis a major focus for innovation. Pancreatic ductal adenocarcinoma (PDCA), a type of pancreatic cancer, is often detected too late, so researchers have developed a new diagnostic tool for this disease. Known as a nanoplasmic sensor assay, the test is designed to spot small markers of cancer in blood plasma. In this case, it identifies tumour-derived extracellular vesicles (tEVs), minute cytoplasmic sacs produced by cells, containing proteins and other molecules characteristic of tumours. The test involves shining a beam of light on a tiny chip, with an array of nanoscale holes, or nanopores (pictured), coated in antibodies specific to PDCA tEVs. Binding of tEVs (shown as multicoloured spheres) to these antibodies causes a shift in the light re-emitted from the chip, enabling detection. Highly sensitive and accurate, this assay should greatly improve our ability to diagnose pancreatic cancer.

Written by Emmanuelle Briolat

You can also follow BPoD on Twitter , Facebook and Instagram

Leave a Reply

Your email address will not be published.